Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Mechanism and general grapefruit pharmacokinetic interaction (increased atorvastatin plasma concentrations) are largely aligned with the provided label sections. However, many grapefruit-related symptom and outcome claims (nausea/vomiting/headache/dizziness/lightheadedness), organ-specific effects (liver-specific), quantified risk increase (up to 50%), and several severity statements are not supported by the supplied label text. Also, the 'avoid grapefruit' instruction is only partially supported by the provided excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) inhibits production of cholesterol in the liver.
12.1 Mechanism of Action (inhibiting HMG-CoA reductase and cholesterol synthesis in the liver)
Lipitor blocks the enzyme HMG-CoA reductase.
12.1 Mechanism of Action (selective, competitive inhibitor of HMG-CoA reductase)
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
12.1 Mechanism of Action (reduces LDL-C; enhances uptake/catabolism via hepatic LDL receptors; reduces LDL production)
CYP3A4 metabolizes Lipitor.
12.3 Pharmacokinetics (in vitro studies suggest importance of CYP3A4 metabolism; increased plasma concentrations after co-administration with CYP3A4 inhibitors)
Consuming grapefruit can increase Lipitor levels in the blood.
7.2 Grapefruit Juice (components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin)
The combination of grapefruit and Lipitor can increase the levels of Lipitor in the blood.
7.2 Grapefruit Juice; 12.3 Table 3 (Grapefruit Juice increases AUC and Cmax)
Elevated Lipitor levels in the blood can lead to muscle damage.
5.1 Skeletal Muscle (myopathy/rhabdomyolysis risk is increased with increased atorvastatin exposure/with strong CYP3A4 inhibitors; provided label does not specifically link grapefruit levels to muscle damage)
Muscle damage can include rhabdomyolysis.
5.1 Skeletal Muscle (rare cases of rhabdomyolysis; myopathy/muscle effects)
Patients should have liver function monitored regularly.
5.2 Liver Dysfunction (LFTs prior to and at 12 weeks following initiation and after dose increases, and periodically thereafter)
Monitoring liver function is intended to detect potential liver damage.
5.2 Liver Dysfunction (monitor until abnormalities resolve; liver enzyme abnormalities guidance)
Unsupported Statements
The reduction of LDL cholesterol helps lower the risk of heart disease and stroke.
Not supported by the provided label text (12.1 excerpt provided does not state heart disease/stroke risk reduction from LDL lowering).
Grapefruit contains furanocoumarins.
Not supported by the provided label text.
Furanocoumarins in grapefruit inhibit the enzyme CYP3A4.
Not supported by the provided label text (7.2 mentions grapefruit juice components inhibit CYP3A4 but does not specify furanocoumarins).
Rhabdomyolysis is a potentially life-threatening condition.
Not supported by the provided label text.
Grapefruit can increase Lipitor levels in the liver.
Not supported by the provided label text (7.2/12.3 provided discuss increased plasma concentrations).
Increased Lipitor levels in the liver can lead to liver damage.
Not supported by the provided label text.
Liver damage can potentially even lead to liver failure.
Not supported by the provided label text.
The combination of grapefruit and Lipitor can cause nausea.
Not supported by the provided label text.
The combination of grapefruit and Lipitor can cause vomiting.
Not supported by the provided label text.
Nausea and vomiting can be severe in some cases.
Not supported by the provided label text.
Increased Lipitor levels in the blood can cause dizziness.
Not supported by the provided label text.
Increased Lipitor levels in the blood can cause lightheadedness.
Not supported by the provided label text.
The grapefruit-Lipitor interaction can cause headaches.
Not supported by the provided label text.
Headaches can be severe in some cases.
Not supported by the provided label text.
The grapefruit-Lipitor interaction can increase the risk of adverse events by up to 50%.
Not supported by the provided label text.
Patients taking Lipitor should avoid products that contain grapefruit extract.
Not supported by the provided label text.
Patients taking Lipitor can choose alternative fruits like oranges, apples, or bananas.
Not supported by the provided label text.
Patients should report side effects to their healthcare provider immediately.
Only partly supported: label text provided advises reporting promptly unexplained muscle pain/tenderness/weakness, but does not provide a general 'immediately' instruction for side effects.
A study published in the Journal of Clinical Pharmacology reported the grapefruit-Lipitor interaction increases adverse event risk.
Not supported by the provided label text.
Contradictions
Important Omissions
Any label-supported counseling specific to grapefruit beyond the provided excerpt (e.g., explicit instruction language matching the full label).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple symptom and severity/outcome claims are not supported by the provided label text, and some risk quantification and organ-specific assertions are unsupported. The mechanism and exposure increase claims for grapefruit are supported, but unsupported downstream effect claims could mislead interpretation of risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many downstream symptom/toxicity and quantified risk claims related to grapefruit-atorvastatin interaction are not supported by the provided label text; 'avoid grapefruit' instruction is only partially supported in the provided excerpts.
Suggested Improvement
Restrict grapefruit-related statements to label-supported content in the provided sections (grapefruit juice can increase atorvastatin plasma concentrations, especially with excessive consumption) and remove unsupported claims about furanocoumarins, specific symptoms, liver-specific increases, quantified (up to 50%) risk, and general immediate side-effect reporting language.